Novo Nordisk raised its full-year outlook after reporting better-than-expected results. However, investors remain focused on pricing pressure, the quality of the earnings beat, and whether the Wegovy pill can become a sufficient growth driver to revive Novo's fortunes.
CEO Mike Doustdar reassured investors that the Wegovy pill can drive profitable growth despite lower prices, stating that rising volumes and the early performance of the pill indicate that the strategy is working.
"We would not be able to... show a positive growth on the top and the bottom if items like the pill were not doing well and were not profitable," Doustdar said.
"Nothing to inspire"
Novo Nordisk's quarterly results and guidance increase did little to alleviate Wall Street's biggest concern: whether the Ozempic maker has a convincing path back to sustainable growth as competition from Eli Lilly intensifies.
Analysts noted that the better-than-expected quarter benefited from rebate adjustments and other temporary factors, while obesity drug sales were broadly in line with expectations.
A future pill market
Novo stated that the improved outlook was driven by increased expectations for GLP-1 product sales, specifically its Wegovy product portfolio, which includes both injectable and pill forms.
Doustdar mentioned, "I could see a future where actually this market is, to a large extent, a pill market," stressing that the launch was only six months old.
